J. Haroche, F. Cohen-aubart, and B. J. Rollins, Histiocytoses: Emerging neoplasia behind inflammation, vol.18, pp.113-125, 2017.

M. Collin, V. Bigley, and K. L. Mcclain, Cell(s) of origin of Langerhans cell histiocytosis, Hematol Oncol Clin North Am, vol.29, pp.825-838, 2015.

C. Rigaud, M. A. Barkaoui, and C. Thomas, Langerhans cell histiocytosis: Therapeutic strategy and outcome in a 30-year nationwide cohort of 1478 patients under 18 years of age, Br J Haematol, vol.174, pp.887-898, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01331987

M. Minkov, N. Grois, and A. Heitger, Response to initial treatment of multisystem Langerhans cell histiocytosis: An important prognostic indicator, Med Pediatr Oncol, vol.39, pp.581-585, 2002.

J. Donadieu, F. Bernard, and M. Van-noesel, Cladribine and cytarabine in refractory multisystem Langerhans cell histiocytosis: Results of an international phase 2 study, Blood, vol.126, pp.1415-1423, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01231424

P. A. Veys, V. Nanduri, and K. S. Baker, Haematopoietic stem cell transplantation for refractory Langerhans cell histiocytosis: Outcome by intensity of conditioning, Br J Haematol, vol.169, pp.711-718, 2015.

S. Héritier, J. F. Emile, and M. A. Barkaoui, BRAF mutation correlates with high-risk Langerhans cell histiocytosis and increased resistance to first-line therapy, J Clin Oncol, vol.34, pp.3023-3030, 2016.

S. Jang and M. B. Atkins, Treatment of BRAF-mutant melanoma: The role of vemurafenib and other therapies, Clin Pharmacol Ther, vol.95, pp.24-31, 2014.

S. Héritier, M. Jehanne, and G. Leverger, Vemurafenib use in an infant for high-risk Langerhans cell histiocytosis, JAMA Oncol, vol.1, pp.836-838, 2015.

A. Kolenová, R. Schwentner, and G. Jug, Targeted inhibition of the MAPK pathway: Emerging salvage option for progressive life-threatening multisystem LCH, Blood Adv, vol.1, pp.352-356, 2017.

, European Medicines Agency: Orphan drug designation. Committee for Orphan Medicinal Products 313647, European Medicines Agency, 2016.

R. Haupt, M. Minkov, and I. Astigarraga, Langerhans cell histiocytosis (LCH): Guidelines for diagnosis, clinical work-up, and treatment for patients till the age of 18 years, Pediatr Blood Cancer, vol.60, pp.175-184, 2013.

A. Heisig, J. Sörensen, and S. Y. Zimmermann, Vemurafenib in Langerhans cell histiocytosis: Report of a pediatric patient and review of the literature, Oncotarget, vol.9, pp.22236-22240, 2018.

J. F. Emile, O. Abla, and S. Fraitag, Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages, Blood, vol.127, pp.2672-2681, 2016.

J. Braier, M. Ciocca, and A. Latella, Cholestasis, sclerosing cholangitis, and liver transplantation in Langerhans cell histiocytosis, Med Pediatr Oncol, vol.38, pp.178-182, 2002.

N. Grois, B. Fahrner, and R. J. Arceci, Central nervous system disease in Langerhans cell histiocytosis, J Pediatr, vol.156, pp.873-881, 2010.

V. R. Nanduri, J. Pritchard, and G. Levitt, Long term morbidity and health related quality of life after multi-system Langerhans cell histiocytosis, Eur J Cancer, vol.42, pp.2563-2569, 2006.

J. Donadieu, C. Piguet, and F. Bernard, A new clinical score for disease activity in Langerhans cell histiocytosis, Pediatr Blood Cancer, vol.43, pp.770-776, 2004.

H. Gadner, N. Grois, and U. Pötschger, Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensification, Blood, vol.111, pp.2556-2562, 2008.

H. Gadner, M. Minkov, and N. Grois, Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis, Blood, vol.121, pp.5006-5014, 2013.

E. A. Eisenhauer, P. Therasse, and J. Bogaerts, New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1), Eur J Cancer, vol.45, pp.228-247, 2009.

J. C. Alvarez, E. Funck-brentano, and A. E. , A LC/MS/MS micro-method for human plasma quantification of vemurafenib. Application to treated melanoma patients, J Pharm Biomed Anal, vol.97, pp.29-32, 2014.

S. Héritier, Z. Hélias-rodzewicz, and H. Lapillonne, Circulating cell-free BRAF V600E as a biomarker in children with Langerhans cell histiocytosis, Br J Haematol, vol.178, pp.457-467, 2017.

V. Taly, D. Pekin, and L. Benhaim, Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients, Clin Chem, vol.59, pp.1722-1731, 2013.
URL : https://hal.archives-ouvertes.fr/inserm-02299581

P. Milne, V. Bigley, and C. M. Bacon, Hematopoietic origin of Langerhans cell histiocytosis and Erdheim-Chester disease in adults, Blood, vol.130, pp.167-175, 2017.

H. Gadner, N. Grois, and M. Arico, A randomized trial of treatment for multisystem Langerhans' cell histiocytosis, J Pediatr, vol.138, pp.728-734, 2001.

S. Weitzman, J. Braier, and J. Donadieu, -CdA) as salvage therapy for Langerhans cell histiocytosis (LCH), Pediatr Blood Cancer, vol.53, issue.2, pp.1271-1276, 2009.

O. S. Eckstein, J. Visser, and C. Rodriguez-galindo, Clinical responses and persistent BRAF V600E + blood cells in children with LCH treated with MAPK pathway inhibition, Blood, vol.133, pp.1691-1694, 2019.

L. Boussemart, E. Routier, and C. Mateus, Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: A study of 42 patients, Ann Oncol, vol.24, pp.1691-1697, 2013.

C. Ma and A. W. Armstrong, Severe adverse events from the treatment of advanced melanoma: A systematic review of severe side effects associated with ipilimumab, vemurafenib, interferon alfa-2b, dacarbazine and interleukin-2, J Dermatolog Treat, vol.25, pp.401-408, 2014.